title: Childhood pemphigus vulgaris successfully treated with rituximab.
abstract: Pemphigus is a potentially fatal autoimmune epidermal bullous disorder. Rituximab is a novel therapy for the treatment of refractory pemphigus. However, there is limited clinical data on safety and efficacy of rituximab in pediatric age group. Herein, we report an 11-year-old boy of childhood pemphigus vulgaris who failed to respond to dexamethasone pulse therapy and was subsequently treated with rituximab and achieved complete remission.
authors.affiliation: Department of Dermatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
authors.forename: Amrinder J
authors.initials: AJ
authors.lastname: Kanwar
authors.forename: Gitesh U
authors.initials: GU
authors.lastname: Sawatkar
authors.forename: Keshavamurthy
authors.initials: K
authors.lastname: Vinay
authors.forename: Takashi
authors.initials: T
authors.lastname: Hashimoto
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D010392:Pemphigus / Q000188:drug therapy* / Q000473:pathology; D011239:Prednisolone / Q000627:therapeutic use; D000069283:Rituximab
chemical_list: D000893:Anti-Inflammatory Agents; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab; D011239:Prednisolone